Tao-Hong-Si-Wu-Tang protects against methionine- and choline-deficient diet-induced hepatic steatosis in rats and is associated with inhibition of oxidative stress, inflammation, apoptosis, and pyroptosis - Report - MDSpire

Tao-Hong-Si-Wu-Tang protects against methionine- and choline-deficient diet-induced hepatic steatosis in rats and is associated with inhibition of oxidative stress, inflammation, apoptosis, and pyroptosis

  • By

  • Luyao Xu

  • Qiuling Li

  • Chengqin Lu

  • Mincheng Zheng

  • Wenhai Guo

  • Yun Chen

  • Jiaying Dai

  • Yao Deng

  • Ning Zhang

  • Kanlin Yang

  • Xinling Chen

  • Kangrong Wang

  • Guohang Yan

  • Hantao Li

  • Rui Duan

  • Jiean Xu

  • Wei Liu

  • Hongzhi Yang

  • Jinwen Xu

  • Min Dai

  • Yaxing Zhang

  • July 6, 2026

  • 0 min

Share

Clinical Report: Tao-Hong-Si-Wu-Tang Mitigates Hepatic Steatosis in Rats

Overview

Tao-Hong-Si-Wu-Tang (THSWT) significantly alleviates hepatic steatosis induced by a methionine- and choline-deficient diet in rats.

Background

Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic liver condition affecting over 30% of adults globally, necessitating effective treatment options. Traditional Chinese medicine (TCM) formulas, such as THSWT, have been explored for their hepatoprotective properties.

Data Highlights

GroupDosage (g/kg)Effect on Hepatic Steatosis
ControlN/AN/A
ModelN/AInduced Steatosis
THSWT Treatment2.5Alleviated Steatosis

Key Findings

  • THSWT treatment (2.5 g/kg/day) alleviated hepatic steatosis in rats fed a methionine- and choline-deficient diet.
  • THSWT reduced levels of hepatic reactive oxygen species (ROS), 3-nitrotyrosine (3-NT), and malondialdehyde (MDA).
  • THSWT increased hepatic glutathione (GSH) levels.
  • THSWT inhibited TLR4/9-IKK-NF-κB-TNF-α/IL-1β/IL-18 innate immune signaling.
  • THSWT suppressed apoptosis and pyroptosis signaling pathways in the liver.

Clinical Implications

Further investigation into the mechanisms of THSWT is needed to understand its role in liver health.

Conclusion

THSWT demonstrates effects in mitigating hepatic steatosis in a rat model.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Tao-Hong-Si-Wu-Tang Mitigates Hepatic Steatosis Induced by Methionine and Choline Deficiency in Rats
  2. Frontiers in Endocrinology — Daixie recipe ameliorates diet-induced MASH in mice via activating PI3K/AKT and Keap1/Nrf2 signaling
  3. The Journal of Infectious Diseases — Decanoylcarnitine Improves Liver Mitochondrial Dysfunction in Hepatitis B Virus Infection by Enhancing Fatty Acid β-Oxidation
  4. Journal of Gastroenterology — Inhibition of C5aR1 Reduces Liver Inflammation and Fibrosis in a NASH Mouse Model Through Modulation of TLR4 Pathway and Macrophage Polarization
  5. Archives of Toxicology — A new transgenic rat model exhibiting non-alcoholic steatohepatitis with fibrosis and cancer development due to connexin 32 deficiency
  6. Clinical care pathway for the risk stratification and management of patients with MASLD
  7. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease
  8. Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease - UCL Discovery

Original Source(s)

Tao-Hong-Si-Wu-Tang protects against methionine- and choline-deficient diet-induced hepatic steatosis in rats and is associated with inhibition of oxidative stress, inflammation, apoptosis, and pyroptosis

  • by Luyao Xu, Qiuling Li, Chengqin Lu, Mincheng Zheng, Wenhai Guo, Yun Chen, Jiaying Dai, Yao Deng, Ning Zhang, Kanlin Yang, Xinling Chen, Kangrong Wang, Guohang Yan, Hantao Li, Rui Duan, Jiean Xu, Wei Liu, Hongzhi Yang, Jinwen Xu, Min Dai, Yaxing Zhang

  • July 6, 2026

Related Content

Immediate prediction of post-ERCP pancreatitis: a novel approach using serum trypsin

Comparison of Care Cascade Outcome Measures for Hepatitis C Among Insured US Adults

ATF3 and HNF4A: an oxidative phosphorylation and cholesterol homeostasis-associated diagnostic and therapeutic repurposing framework target for metabolic dysfunction-associated steatohepatitis patients